These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 22781459

  • 1. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X, Sun WJ, Chen SL, Zhong YP, An N, Hu Y, Zhang JJ, Liu XH.
    Zhonghua Yi Xue Za Zhi; 2012 Mar 27; 92(12):838-41. PubMed ID: 22781459
    [Abstract] [Full Text] [Related]

  • 2. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhong YP, Chen SL.
    Zhonghua Nei Ke Za Zhi; 2009 May 27; 48(5):396-8. PubMed ID: 19615158
    [Abstract] [Full Text] [Related]

  • 3. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA.
    Am J Hematol; 2014 Aug 27; 89(8):803-8. PubMed ID: 24757085
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Hughes M, Micallef-Eynaud P.
    Clin Lab Haematol; 2006 Aug 27; 28(4):267-9. PubMed ID: 16898968
    [Abstract] [Full Text] [Related]

  • 5. Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
    Fukushima T, Nakamura T, Miki M, Sakai T, Iwao H, Nakajima A, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Hirose Y, Umehara H.
    Anticancer Res; 2010 Sep 27; 30(9):3791-4. PubMed ID: 20944171
    [Abstract] [Full Text] [Related]

  • 6. Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
    Zhang J, Zhong Y.
    Hematol Oncol; 2015 Jun 27; 33(2):75-9. PubMed ID: 24395149
    [Abstract] [Full Text] [Related]

  • 7. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS, Jung SH, Yang DH, Bae SY, Kim YK, Kim HJ, Lee JJ.
    Clin Lymphoma Myeloma Leuk; 2014 Oct 27; 14(5):389-94. PubMed ID: 24630919
    [Abstract] [Full Text] [Related]

  • 8. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
    Liang Z, Ren H, Cen X, Li Y, Wang L, Ou J, Dong Y, Yin Y, Wang W, Liu W, Wang Q, Qiu Z, Wang M, Xu W, Sun Y.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar 27; 35(3):225-30. PubMed ID: 24666489
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 11. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG.
    J Clin Oncol; 2013 Feb 01; 31(4):448-55. PubMed ID: 23233713
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L, Tang W, Wang Y, Xu L, Zhao WL, Wu W, Chen YB, Shen ZX, Hu J.
    Zhonghua Xue Ye Xue Za Zhi; 2011 May 01; 32(5):308-12. PubMed ID: 21729598
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators.
    N Engl J Med; 2008 Aug 28; 359(9):906-17. PubMed ID: 18753647
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J, Scudla V, Ordeltova M, Bacovsky J, Pika T, Langova K.
    Eur J Haematol; 2009 Dec 01; 83(6):528-34. PubMed ID: 19624720
    [Abstract] [Full Text] [Related]

  • 16. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.
    Cancer; 2007 Sep 01; 110(5):1042-9. PubMed ID: 17654660
    [Abstract] [Full Text] [Related]

  • 17. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG, Jin J, Huang XJ, Li Y, Chen WM, Liu ZG, Chen XQ, Shen ZX, Hou J.
    Chin Med J (Engl); 2011 Oct 01; 124(19):2969-74. PubMed ID: 22040537
    [Abstract] [Full Text] [Related]

  • 18. Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
    SAWADA T, NAJIMA Y, OHASHI K, KATO I, MIYAZAWA M, NAKANO M, KOBAYASHI T, YAMASHITA T, AKIYAMA H, SAKAMAKI H.
    Rinsho Ketsueki; 2009 Nov 01; 50(11):1635-40. PubMed ID: 20009440
    [Abstract] [Full Text] [Related]

  • 19. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC, León-Villar J, de Arriba de la Fuente F, Moreno Belmonte MJ, Iranzo Fernández MD.
    Farm Hosp; 2012 Nov 01; 36(4):275-81. PubMed ID: 22115856
    [Abstract] [Full Text] [Related]

  • 20. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul 01; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.